Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients

• Status: Completed
• Trial end date: 2009-09-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Ganciclovir; Ganciclovir triphosphate; Maribavir

Criteria

Inclusion Criteria:

• Orthotopic liver transplant recipient

• Donor CMV seropositive / Recipient CMV seronegative

• Enrolled within 10 days after liver transplant

• Able to swallow tablets

Exclusion Criteria:

• Multiple organ transplant

• HIV infection

• CMV disease

• Use of other anti-CMV therapy at time of enrollment